Cecilia J Proietti Selected Research

Cecilia J Proietti Research Topics

Disease

27	Breast Neoplasms (Breast Cancer) 12/2023 - 08/2002
20	Neoplasms (Cancer) 01/2023 - 08/2002
6	Carcinogenesis 04/2013 - 02/2003
4	Triple Negative Breast Neoplasms 12/2023 - 01/2020
4	Neoplasm Metastasis (Metastasis) 12/2017 - 08/2002
3	Adenocarcinoma 07/2004 - 02/2003
1	Genomic Instability 07/2021
1	Melanoma (Melanoma, Malignant) 01/2020
1	Oncogene Addiction 01/2020
1	Carcinoma (Carcinomatosis) 12/2017

Drug/Important Bio-Agent (IBA)

19	Progesterone Receptors (Progesterone Receptor)IBA 12/2023 - 02/2003
8	Progestins (Progestagens)IBA 12/2014 - 02/2003
6	Estrogens (Estrogen)FDA Link 01/2022 - 06/2007
4	Protein Isoforms (Isoforms)IBA 12/2023 - 02/2003
4	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 12/2023 - 03/2011
4	Trastuzumab (Herceptin)FDA Link 01/2023 - 07/2010
4	Messenger RNA (mRNA)IBA 07/2021 - 01/2004
4	Neuregulin-1 (Neuregulin 1)IBA 10/2015 - 08/2002
4	Mitogen-Activated Protein Kinase 3IBA 04/2013 - 01/2004
4	Progesterone FDA LinkGeneric 04/2012 - 02/2003
3	SteroidsIBA 12/2023 - 03/2009
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 08/2002
3	Hormones (Hormone)IBA 10/2020 - 03/2009
3	Biomarkers (Surrogate Marker)IBA 10/2020 - 02/2012
3	histidine-rich proteinsIBA 03/2009 - 08/2002
3	Somatomedin Receptors (Somatomedin Receptor)IBA 03/2006 - 01/2004
3	OligodeoxyribonucleotidesIBA 03/2006 - 01/2004
3	Medroxyprogesterone Acetate (Depo-Provera)FDA LinkGeneric 07/2004 - 02/2003
2	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 11/2023 - 12/2013
2	LigandsIBA 12/2019 - 01/2018
2	Tamoxifen FDA LinkGeneric 01/2018 - 12/2013
2	Estrogen ReceptorsIBA 12/2017 - 12/2013
2	Phosphotransferases (Kinase)IBA 10/2015 - 03/2009
2	tyrosine receptor (receptor, tyrosine)IBA 10/2015 - 03/2009
2	Proteins (Proteins, Gene)FDA Link 12/2014 - 02/2003
2	CytokinesIBA 08/2012 - 07/2010
2	NF-kappa B (NF-kB)IBA 07/2010 - 02/2008
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2010 - 02/2008
2	Peptide Hydrolases (Proteases)FDA Link 06/2007 - 08/2002
2	Progesterone CongenersIBA 07/2004 - 02/2003
2	Insulin Receptor Substrate ProteinsIBA 07/2004 - 01/2004
2	Tyrosine (L-Tyrosine)FDA Link 07/2004 - 01/2004
2	Mitogen-Activated Protein KinasesIBA 07/2004 - 02/2003
1	RNA (Ribonucleic Acid)IBA 07/2021
1	6-methyladenineIBA 07/2021
1	MethyltransferasesIBA 07/2021
1	Phenobarbital (Luminal)FDA Link 10/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2018
1	Transcription Factors (Transcription Factor)IBA 01/2018
1	Glycoproteins (Glycoprotein)IBA 12/2017
1	human ERBB2 proteinIBA 12/2017
1	Blocking AntibodiesIBA 02/2017
1	MucinsIBA 02/2017
1	Mucin-4IBA 02/2017
1	Cyclin A2IBA 12/2014
1	Cyclin D1IBA 12/2013
1	Cyclin-Dependent Kinase Inhibitor p21IBA 06/2013
1	ChemokinesIBA 08/2012
1	Monoclonal AntibodiesIBA 07/2010
1	3- (4- methylphenylsulfonyl)- 2- propenenitrileIBA 02/2008
1	Type I Tumor Necrosis Factor ReceptorsIBA 02/2008
1	Type II Tumor Necrosis Factor ReceptorsIBA 02/2008
1	HSP70 Heat-Shock Proteins (Heat-Shock Protein 70)IBA 03/2006
1	Fas Ligand Protein (Fas Ligand)IBA 03/2006
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 07/2004
1	Phosphatidylinositols (Phosphatidylinositol)IBA 08/2002
1	Plasminogen Activators (Plasminogen Activator)IBA 08/2002
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 08/2002
1	heregulin beta1IBA 08/2002

Therapy/Procedure

4	Therapeutics 11/2023 - 12/2013
2	Immunotherapy 01/2020 - 08/2012
1	Drug Therapy (Chemotherapy) 12/2017